甲基丙二酸血症伴高胱氨酸尿症
Methylmalonic acidemia with homocystinuria
定义 英文原文(暂无中文)
A rare inborn error of vitamin B12 (cobalamin) metabolism characterized by megaloblastic anemia, lethargy, failure to thrive, developmental delay, intellectual deficit and seizures. There are four complementation classes of cobalamin defects (cblC, cblD, cblF and cblJ) that are responsible for methylmalonic acidemia - homocystinuria (methylmalonic acidemia - homocystinuria cblC, cblD cblF and cblJ).
别名
腺苷钴胺素和甲基钴胺素合成联合缺陷
基本事实
- 遗传方式
- 常染色体隐性、X 连锁隐性
- 发病年龄
- 各年龄段
相关基因 5来自下位疾病
Orphanet 未在本条目上直接标注致病基因。下表由本组所属的下位疾病汇总而来,「来源条目」列给出基因实际标注在哪一个 ORPHA 条目上。
| 基因 | 名称 | 来源条目 |
|---|---|---|
| ABCD4 | ATP binding cassette subfamily D member 4 | ORPHA:369955 |
| HCFC1 | host cell factor C1 | ORPHA:369962 |
| LMBRD1 | LMBR1 domain containing 1 | ORPHA:79284 |
| MMACHC | metabolism of cobalamin associated C | ORPHA:79282 |
| MMADHC | metabolism of cobalamin associated D | ORPHA:79283 |
临床表型 18
极常见 99–80%12
- 弱视 HP:0000646
- 发育迟滞 HP:0001508
- 疲乏 HP:0012378
- 喂养困难 HP:0011968
- 全面发育迟缓 HP:0001263
- 肌张力减退 HP:0001252
- 智力障碍 HP:0001249
- 昏睡 HP:0001254
- 巨幼细胞性骨髓 HP:0001980
- 小头畸形 HP:0000252
- 视网膜病变 HP:0000488
- 癫痫发作 HP:0001250
常见 79–30%5
- 心血管系统形态异常 HP:0030680
- 运动异常 HP:0100022
- 非典型行为 HP:0000708
- 步态异常 HP:0001288
- 脑积水 HP:0000238
偶见 29–5%1
- 皮疹 HP:0000988
近两年的全球研究 34L2
2024/08 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。
- 2026-05综述病例报告开放获取A child with cobalamin C deficiency caused by complex heterozygous variation of c.567dupT and c.80A > G complicated with pulmonary arterial hypertension and hydrocephalus: A case report and literature review
- 2026-04开放获取Sublingual methylcobalamin treatment in infants with prolonged jaundice due to vitamin B12 deficiency
- 2026-03病例报告开放获取Encephalitis-like presentation of methylmalonic acidemia with homocystinuria in a postpartum woman: a case report
- 2026-01病例报告开放获取Case Report: Dilated cardiomyopathy as the initial presentation in an adult with late-onset CblC defect
- 2025-12开放获取Uncovering the genetic architecture of ME/CFS: a precision approach reveals impact of rare monogenic variation
- 2025-12Underrecognized need for early detection of inborn errors of metabolism in China: A population-based study of 14.31 million residents (2012-2023)
- 2025-10病例报告开放获取Case Report: Cerebellar microhemorrhages: an underrecognized feature of MMA-HC revealed by high-field 7.0 T MRI
- 2025-09综述The SLC-ome of membrane transport: From molecular discovery to physiology and clinical applications
- 2025-09开放获取Milder Form of Cobalamin C Disease May Be Missed by Newborn Screening: The Importance of Methylmalonic Acid Assessment
- 2025-08开放获取Analysis of hydroxocobalamin dosage in patients with CblC deficiency
- 2025-08开放获取Spectrum and epidemiology of rare diseases in a Chinese natural population of 14.31 million residents, 2012-2023
- 2025-07综述开放获取Amino Acid Metabolism in Liver Mitochondria: From Homeostasis to Disease
- 2025-06开放获取Few shot learning for phenotype-driven diagnosis of patients with rare genetic diseases
- 2025-06Variable phenotypes and outcomes associated with the MMACHC c.1A>G variant in Chinese patients with combined methylmalonic acidemia and homocystinuria cblC type
- 2025-06综述开放获取Advances in Complement Inhibitory Strategies for the Treatment of Glomerular Disease: A Rapidly Evolving Field
- 2025-05综述开放获取From Nutrient to Nanocarrier: The Multifaceted Role of Vitamin B12 in Drug Delivery
- 2025-05综述病例报告开放获取Retinal Changes in Early-Onset cblC Methylmalonic Acidemia Identified Through Expanded Newborn Screening: Highlights from a Case Study and Literature Review
- 2025-05New genetic tools to define the pathophysiology of inborn errors of cobalamin metabolism impacting mammalian development
- 2025-05开放获取Propionyl Carnitine Metabolic Profile: Optimizing the Newborn Screening Strategy Through Customized Cut-Offs
- 2025-04综述开放获取Updated Gene Therapy for Renal Inborn Errors of Metabolism
境外已获批用于本病的药物 0L2
欧盟与美国均未检索到已获批用于本病的药物。
已获孤儿药资格、尚未获批的在研药物(1 项)
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励,不代表这个药已被证明有效,也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- messanger ribonucleic acid (mRNA)-based therapeutic agent encoding hum美国2018-03-07Treatment of isolated methylmalonic academia (MMA) due to methylmalonyl-Coenzyme A mutase (MUT) deficiency官方记录
数据来自欧洲药品管理局(EMA)的药品与孤儿药资格公开导出表,以及美国 FDA 孤儿药资格数据库。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。
中国境外的在招试验 1L2
这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。
共 2 项。
- 尚未开始招募NCT07163364A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type)
- 招募中NCT04880356Longitudinal Study of Ultra-rare Inherited Metabolic and Degenerative Neurological Diseases.意大利
外部标识与链接
发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
- 中文病名:Orphanet 中文包,冻结于 2020-06-01
- 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)